AKESO: DATE OF BOARD MEETING
Daiwa Keeps Their Buy Rating on Akeso, Inc. (9926)
Guotai Haitong: Alzheimer’s Disease Ushers in a New Era of Disease-Modifying Therapies, with Domestic Companies Demonstrating Strong Competitiveness in Pipeline Development
China's neurodegenerative disease drug market was valued at approximately USD 2.6 billion in 2025 and is projected to reach USD 5.5 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 16.0%, significantly outpacing the global growth rate of 8.1%.
The National Development and Reform Commission (NDRC) convened a symposium on the development of the biopharmaceutical industry at the end of last month.
The Price Cost and Certification Center of the National Development and Reform Commission (NDRC) organized a symposium with selected domestic innovative biopharmaceutical companies on July 30 to gain insights into emerging trends, new challenges, and future development trajectories in the biopharmaceutical industry, and to solicit opinions and suggestions for subsequent research initiatives.
Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC
Interest in semiconductor industry research has been overtaken.
Recently, innovative pharmaceuticals have experienced a rebound, significantly boosting market interest in the pharmaceutical and biotechnology sector.